Intra-Cellular Therapies Inc. - ITCI STOCK NEWS

Intra-Cellular Therapies has received FDA approval for two new dosage strengths of CAPLYTA (lumateperone): 10.5 mg and 21 mg. These adapt dosage recommendations for patients on moderate or strong CYP3A4 inhibitors and those with moderate to severe hepatic impairment. CAPLYTA is indicated for the treatment of schizophrenia and bipolar depression, demonstrating efficacy with a favorable safety profile. The new dosages will be available mid-2022, further enhancing the medicine's accessibility for specific patient populations.

Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) announced the appointment of E. Rene Salas to its Board of Directors, where he will also serve on the audit committee. With over 35 years in financial and life sciences advisory roles, Salas brings valuable experience, having previously worked at Ernst & Young, LLP and served as CFO of Wellstat, LLC. His expertise is expected to support Intra-Cellular's growth and mission to develop innovative CNS therapies, enhancing operational oversight and strategic direction.

Intra-Cellular Therapies, a biopharmaceutical company focused on CNS disorders, announced that CEO Sharon Mates will present at the 21st Annual Needham Virtual Healthcare Conference on April 12, 2022, at 11:00 am ET. The presentation will be accessible live and archived on the company's website under the Investor Relations section. The company's innovative treatments are based on Nobel prize-winning research aimed at understanding cell interactions. For more details, visit www.intracellulartherapies.com.

Intra-Cellular Therapies received FDA approval for CAPLYTA® (lumateperone) as the first treatment for bipolar depression in adults. In Q4 2021, the company reported total revenues of $25.7 million, a 106% increase year-over-year, with CAPLYTA net product revenues at $25.5 million. For the full year, total revenues reached $83.8 million, up 267%. Despite strong revenue growth, the net loss for 2021 was $284.1 million, reflecting increased R&D and SG&A expenses. CAPLYTA prescriptions rose 15% in Q4 compared to Q3 2021, showcasing strong demand.

Intra-Cellular Therapies (Nasdaq: ITCI) announced a conference call on March 1, 2022, at 8:30 a.m. ET to discuss its corporate updates and financial results for the year ending December 31, 2021. To participate, dial 1-(844) 835-6563 or 1-(970) 315-3916 internationally, using conference ID 5899935. The presentation will be available live and archived in the Investor Relations section on their website. Founded on Nobel prize-winning research, Intra-Cellular focuses on innovative treatments for CNS disorders.

Intra-Cellular Therapies (Nasdaq: ITCI) announced that CEO Sharon Mates, Ph.D., will present at the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022, at 8:40 am ET. Attendees can access the live and archived webcast through the Investor Relations section of the company's website. Intra-Cellular Therapies focuses on innovative treatments for central nervous system disorders, leveraging Nobel prize-winning research to understand cellular impacts of therapies. For more details, visit www.intracellulartherapies.com.

Intra-Cellular Therapies (Nasdaq: ITCI) has successfully completed a public offering of 9,523,810 shares at $42.00 each, raising approximately $460 million in gross proceeds. The underwriters fully exercised their option for an additional 1,428,571 shares. After deductions, the net proceeds amount to around $433.7 million. The offering was conducted under a shelf registration statement with the SEC. This infusion of capital aims to support the company's ongoing development of therapeutics for central nervous system disorders.

Intra-Cellular Therapies (ITCI) announced the pricing of a public offering of 9,523,810 shares at $42.00 each, totaling $400 million in gross proceeds. The offering will close on January 7, 2022, subject to customary conditions. Underwriters have a 30-day option to purchase an additional 1,428,571 shares. This is part of a shelf registration statement filed with the SEC. The funds raised will support ongoing development of CNS therapeutics, enhancing the company's financial position and growth prospects.

Intra-Cellular Therapies (Nasdaq: ITCI) has initiated a public offering of $400 million in shares of its common stock, with underwriters given a 30-day option to purchase an additional 15% of the shares. The offering is part of a shelf registration statement effective with the SEC. J.P. Morgan, SVB Leerink, and others are acting as joint book-running managers. The offering is subject to market conditions, with no assurance on completion or terms.